The Price of Secrecy: Austria’s Constitutional Showdown Over Keytruda’s Hidden Costs

By Investigative Desk

A high-stakes legal battle is unfolding in Austria, representing a critical stress test for the nation’s fledgling transparency laws. At the center of the dispute is Keytruda, the blockbuster cancer immunotherapy developed by Merck & Co. (known as MSD outside the U.S.). The core question—one that has pitted investigative journalists against one of the world’s most powerful pharmaceutical giants—is simple yet profound: Does the public have a right to know exactly how much taxpayer money is being funneled into the coffers of a private corporation for life-saving medication?

As the case ascends to Austria’s Constitutional Court, the outcome threatens to reshape the power dynamic between national healthcare systems and the pharmaceutical industry, potentially dismantling a culture of administrative secrecy that has persisted for over a century.

The Genesis of the Dispute: A "Cancer Calculus"

The legal confrontation traces its roots to the Cancer Calculus project, a massive, year-long global investigation led by the International Consortium of Investigative Journalists (ICIJ). Working in tandem with Austrian media outlets profil and Der Standard, reporters sought to peel back the layers of mystery surrounding drug procurement in Austria.

Their investigation revealed that Keytruda is the single largest medication expense for Austrian public hospitals. Based on the manufacturer’s publicly listed prices, the drug cost the Austrian system an estimated 245 million euros in 2024 alone, with the total expenditure between 2020 and 2024 exceeding 900 million euros.

However, these figures are merely "list prices"—the top-line numbers that rarely reflect the actual cost paid by the state. Due to opaque, ironclad confidentiality clauses embedded in contracts between hospital networks and Merck, even the federal health authorities remain in the dark regarding the final, negotiated prices paid after secret rebates.

A New Era of Transparency?

In September 2025, Austria enacted a landmark freedom-of-information law. This legislation was designed to dismantle a 100-year-old constitutional rule that had effectively shielded the inner workings of government from public scrutiny. For journalists, this was a watershed moment.

Armed with the new law, reporters from profil and Der Standard filed formal requests to obtain the "net" prices paid by hospitals in all nine federal states for Keytruda. Their goal was to move beyond estimates and expose the reality of public spending on a drug that represents a massive burden on the national health budget.

When those requests were denied, the journalists did not back down. They initiated a series of challenges in regional administrative courts, arguing that the public interest in understanding the procurement of high-cost, essential medicine outweighs the private interest of a pharmaceutical corporation in maintaining trade secrecy.

Chronology: From Records Requests to the Supreme Court

• September 2025: Austria’s new freedom-of-information law takes effect, ending a century of government secrecy and opening the door for investigative transparency.
• Late 2025: Journalists from profil and Der Standard file requests across all nine Austrian states, seeking the actual, post-discount prices paid by public hospitals for Keytruda.
• Spring 2026: Following widespread denials, reporters initiate legal challenges in regional administrative courts. In many instances, they argue their own cases without formal legal counsel, emphasizing the public’s "right to know."
• May 2026: Court orders reveal that Merck is aggressively opposing the disclosures, claiming that revealing net pricing would constitute a breach of trade secrets and harm its global competitive standing.
• June 2026: Administrative courts issue split decisions. Tyrol and Burgenland rule in favor of the journalists, while others reject the requests.
• July 2026: Merck formally appeals the Tyrol decision, escalating the matter to Austria’s Constitutional Court and challenging the constitutionality of the transparency law itself.

The Argument for Secrecy vs. The Public Right to Know

Merck’s Defense: Trade Secrets and Global Strategy

Merck’s legal strategy is multifaceted. The company argues that the disclosure of net prices would provide an "informational advantage" to competitors, effectively stripping the company of its ability to negotiate fairly in a global market. Furthermore, they have invoked the specter of U.S. policy, specifically the "Most Favored Nation Drug Pricing" initiative. Merck contends that if Austria’s lower, negotiated prices were made public, it could trigger a ripple effect, forcing the company to harmonize global prices downward—a scenario they claim would be commercially damaging.

The Journalists’ Position: Public Interest as Paramount

Stefan Melichar, a profil reporter and ICIJ member, has been a vocal advocate for the disclosure. "This is a hugely untested territory," Melichar told the ICIJ. "Nevertheless, for us it is clear that information on big public procurement cases, like those regarding Keytruda, is of paramount public interest."

The legal team representing the journalists, led by Michael Borsky, has cautioned that the ongoing litigation could create a "chilling effect." If the court allows corporations to effectively veto transparency laws, it could discourage journalists from ever utilizing the new legislation, effectively rendering the law toothless.

Supporting Data: The Global Context of Drug Pricing

The Cancer Calculus investigation found that the lack of transparency in Austria is symptomatic of a global systemic issue. By filing over 1,000 public records requests across 27 countries, the ICIJ discovered that list prices are frequently used as a smokescreen to hide the true, lower prices negotiated through secret rebates.

• Price Volatility: The investigation documented extreme price disparities. A single 100mg vial of Keytruda costs approximately $850 in Indonesia, compared to $6,015 in the United States.
• The "Blindfolded" Negotiator: Sabine Vogler, a senior expert at the Austrian National Public Health Institute (Gesundheit Österreich GmbH), has been highly critical of the current system. She notes that confidential discount structures leave governments negotiating "blindfolded," as they have no benchmark to determine if they are securing a fair market price compared to their neighbors.
• Economic Impact: In Austria, a standard 200mg dose carries a list price of 6,800 euros. Without access to the rebate structure, the true cost remains a "black box," making it impossible for taxpayers to evaluate the efficiency of their healthcare spending.

Implications: A Precedent for European Healthcare

The Constitutional Court’s upcoming ruling will be far-reaching. If the court upholds the right to transparency, it will establish a significant legal precedent in Europe, potentially emboldening other nations to challenge the confidentiality clauses that have historically protected the pharmaceutical industry from scrutiny.

Conversely, if the court sides with Merck, it would signal that the power of corporate contract law and "trade secrets" carries more weight than the public’s right to fiscal transparency in matters of life-saving medicine.

A Call for Accountability

The investigation has already prompted legislative stirrings. In the state of Vorarlberg, local lawmakers launched a formal inquiry after the high list prices of Keytruda were publicized, calling the lack of price transparency "unacceptable."

As the legal proceedings continue, the case has evolved into a proxy war for the future of democratic oversight in the medical sector. With hospitals claiming that transparency could weaken their bargaining position and journalists insisting that public money demands public accountability, the Austrian Constitutional Court finds itself at a crossroads.

Ultimately, the case is not just about a single drug or a single company. It is a fundamental debate about the limits of commercial confidentiality in a democratic society. As the judiciary prepares to weigh in, one thing remains clear: the days of "blindfolded" negotiations may be drawing to a close, as the demand for accountability in the multi-billion-dollar pharmaceutical market continues to grow.

Merck and its Austrian subsidiary, Merck Sharp & Dohme Gesellschaft m.b.H, have declined to provide comment on the ongoing litigation, leaving the courtroom as the final arbiter in a struggle that will undoubtedly echo far beyond the borders of Austria.